Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | AGER | Q15109 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247560 | 0.87 | AGER (0.62) | FDPSAGERCYP19A1 | |
| Hydrochloric Acid SCHEMBL1775858 | 0.85 | AGER (0.60) | FDPSAGERCYP19A1 | |
| SCHEMBL10730735 | 0.82 | AGER (0.53) | FDPSAGERCYP19A1 | |
| SCHEMBL11292777 | 0.82 | AGER (0.53) | FDPSAGERCYP19A1 | |
| SCHEMBL1585079 | 0.82 | AGER (0.53) | FDPSAGERCYP19A1 | |
| SCHEMBL143375 | 0.80 | CYP19A1 (0.51) | FDPSAGERCYP19A1 | |
| SCHEMBL412063 | 0.80 | AGER (0.51) | FDPSAGERCYP19A1 | |
| Hydrochloric Acid SCHEMBL11288977 | 0.80 | AGER (0.51) | FDPSAGERCYP19A1 | |
| Hydrochloric Acid SCHEMBL10730868 | 0.80 | AGER (0.51) | FDPSAGERCYP19A1 | |
| SCHEMBL17934931 | 0.80 | AGER (0.51) | FDPSAGERCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | claimed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | claimed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | claimed |
| US-7087756-B2 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2006-08-08 | — | — | US | disclosed |
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248893-A1 | Isoxazolopyridinones | XDH, NPY1R, TBXA2R | FDPS 617/4885AGER 2894/4885CYP19A1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.